Legend Biotech (LEGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell ...
Scotiabank analyst George Farmer maintained a Buy rating on Legend Biotech (LEGN – Research Report) today and set a price target of ...
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly ...
Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings ...
After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...
Investor's Business Daily on MSN1h
Legend Biotech Rises After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%Legend Biotech jumped Monday after the company said its J&J-tied multiple myeloma drug, Cavykti, cut the risk of death.
Legend Biotech's valuation is conservative, suggesting potential for significant appreciation and growth ahead. Click here to ...
After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first ...
On Friday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $49.27 which represents a slight increase of $2.42 or 5.17% from the prior close of $46.85. The stock opened at ...
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback